Biotech IPOs & momentum in the IL-18 field: BioCentury’s latest podcast

Plus: the schizophrenia pipeline and what’s next for Singapore biotech

NASDAQ’s first biotech public listings of 2024 provided hopeful signs for a rebound in the biotech IPO market. On the latest BioCentury This Week podcast, BioCentury’s editors assess the performance of IPOs by CG Oncology Inc. (NASDAQ:CGON) and ArriVent BioPharma Inc. (NASDAQ:AVBP) and what’s next for the IPO market.

They also discuss how the growing IL-18 field aims to enhance cell therapies via decoy evasion and look ahead to the schizophrenia milestones coming this year.

Finally, the editors size up the Singapore biotech ecosystem and what the country needs to do to cement a position on the global biotech map.

Join BioCentury, BayHelix and McKinsey March 4-6 in Singapore for the third East-West Biopharma Summit. For information on how to sponsor The BioCentury Show and the BioCentury This Week podcast, please contact BioCentury at conferences@biocentury.com.